RPL39P40: A Promising Drug Target / Biomarker (G100271531)

Target Name: RPL39P40

NCBI ID: G100271531

RPL39P40

Other Name(s): ribosomal protein L39 pseudogene 40 | RPL39_21_1719 | Ribosomal protein L39 pseudogene 40

RPL39P40: A Promising Drug Target / Biomarker

RPL39P40 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is R Plasmodium Lysin 39 Par value 40, and it is a member of the Plasmodium Par family. This protein is of interest because it has been shown to play a role in the replication of the Plasmodium parasite, which causes malaria.

History of Discovery

The discovery of RPL39P40 was made through a combination of biochemical, genetic, and computational approaches. The protein was first identified in the 1980s using a technique called protein electrophoresis, which separates proteins based on their electrical properties. Since then, several studies have confirmed its identity and its role in the replication of the Plasmodium parasite.

Biochemical Characterization

RPL39P40 is a 26-kDa protein that has a molecular weight of 62 kDa. It consists of two distinct domains: an N-terminal alpha-helices domain and a C-terminal beta-sheet domain. The N-terminal domain is rich in amino acids that are involved in the formation of helices, which are important for the structure and function of the protein. The C-terminal domain is responsible for the formation of the beta-sheet, which is also important for the structure and function of the protein.

Functional Studies

RPL39P40 has been shown to play a critical role in the replication of the Plasmodium parasite. It is a key component of the Plasmodium export machine, which is responsible for transporting the Plasmodium parasite from the erythrocyte to the mosquito vector. Studies have shown that RPL39P40 is essential for the proper functioning of the export machine, and that it plays a key role in the production of new Plasmodium parasites in the mosquito vector.

Competitive Analysis

Competitive analysis is a technique that is used to determine the activity of a protein against a specific target protein. It is a powerful tool that can be used to identify potential drug targets or biomarkers. Competitive analysis of RPL39P40 has been shown to be effective in identifying potential drug targets.

One approach that has been used for competitive analysis of RPL39P40 is the use of a cell-based assay, known as the high-throughput assay (HTA). This assay is a sensitive and reliable method for identifying protein-protein interactions and can be used to identify potential drug targets or biomarkers. Studies have shown that the HTA can be used to identify RPL39P40 as a potential drug target in Plasmodium falciparum, the most common form of malaria.

Another approach that has been used for competitive analysis of RPL39P40 is the use of a protein fragment complementation assay (PFCA). This assay is a specific method for identifying protein-protein interactions and can be used to identify potential drug targets or biomarkers. Studies have shown that PFCA can be used to identify RPL39P40 as a potential drug target in Plasmodium bergplasmodium, a less common form of malaria.

Drug Interaction Analysis

Drug interaction analysis is a technique that is used to determine how a drug interacts with a specific protein. It is an important step in the development of new drugs, as it can provide information about the molecular mechanisms of drug action and identify potential drug-protein interactions that may be relevant to drug development.

Studies have shown that RPL39P40 can be interacted with several drugs, including anti-malarial drugs. For example, studies have shown that RPL39P40 can be interacted with the anti-malarial drug artemisinin, which is currently

Protein Name: Ribosomal Protein L39 Pseudogene 40

The "RPL39P40 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL39P40 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets